SCHEMBL3301628

SCHEMBL3301628

CC1CCN(N2CCCCC2)C1

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.35
POLB P06746 1/20 0.34
HRH3 Q9Y5N1 1/20 0.32
PHGDH O43175 1/20 0.32
MGLL Q99685 1/20 0.32
ALDH1A1 P00352 2/20 0.31
LMNA P02545 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
CHRM3 P20309 2/20 0.30
PDE4A P27815 2/20 0.30
PDE4B Q07343 2/20 0.30
PDE4C Q08493 2/20 0.30
PDE4D Q08499 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7497886 0.98 ACHE (0.34) ACHEPOLBHRH3PHGDHMGLL
Bromide SCHEMBL8688240 0.98 ACHE (0.34) ACHEPOLBHRH3PHGDHMGLL
SCHEMBL726800 0.97 PHGDH (0.33) ACHEPOLBPHGDHMGLLALDH1A1
SCHEMBL10451712 0.90 ALDH1A1 (0.38) ACHEPOLBALDH1A1LMNAMEN1
SCHEMBL727807 0.88 ALDH1A1 (0.37) ACHEPOLBPHGDHMGLLALDH1A1
SCHEMBL3446740 0.87 ALDH1A1 (0.39) POLBALDH1A1LMNAMEN1KMT2A
SCHEMBL8802556 0.87 ACHE (0.44) ACHEPOLBHRH3PHGDHMGLL
Hydrochloric Acid SCHEMBL7497872 0.85 ALDH1A1 (0.38) POLBALDH1A1LMNAMEN1KMT2A
Bromide SCHEMBL8688236 0.85 ALDH1A1 (0.38) POLBALDH1A1LMNAMEN1KMT2A
SCHEMBL10982018 0.84 ACHE (0.41) ACHEPOLBHRH3PHGDHMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2010-04-15 US disclosed
EP-2118092-A1 NEW N, N'- 2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS Sanofi-Aventis (FR) 2009-11-18 EP disclosed
WO-2009056693-A1 NOVEL DERIVATIVES OF N, N'- 2, 4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS MEDICAMENTS PHARMACEUTICAL COMPOSITIONS AND IN PARTICULAR AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2009-05-07 WO disclosed
WO-2008099073-A1 N, N' -2, 4-DIANILINOPYRIMIDINES PREPARATION AND USE THEREOF AS IKK INHIBITORS PREPARATION AND TEH PHARMACUETICAL COMPOSITIONS THEREOF SANOFI-AVENTIS (FR) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS CHUK, IKBKB, IKBKE ACHE 1947/4885POLB 1036/4885HRH3 3750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.